ER-NEGATIVE BREAST CANCER

Clinical trials for ER-NEGATIVE BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new ER-NEGATIVE BREAST CANCER trials appear

Sign up with your email to follow new studies for ER-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Terminated 1

New drug combo tested to shrink aggressive breast cancer before surgery

Disease control Recruiting now

This study is testing whether the drug sacituzumab govitecan, alone or combined with pembrolizumab, can shrink tumors before surgery in people with localized triple-negative breast cancer. About 260 participants will receive the study treatment for up to 12 weeks, followed by sta…

Matched conditions: ER-NEGATIVE BREAST CANCER

Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

ER-NEGATIVE BREAST CANCER

Get alerted when new ER-NEGATIVE BREAST CANCER trials appear

New drug combo tested to shrink aggressive breast cancer before surgery